– Series A financing co-led by Third Rock Ventures, RTW and Perceptive Xontogeny Venture Fund, and includes new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, T. Rowe Price, Cormorant Asset Management and Piper Heartland with participation from existing seed investors
– Initial Phase 1 results with CARGO’s CD22 CAR T-cell therapy demonstrated durable complete responses in greater than 50% of patients with large B-cell lymphoma (LBCL) that is relapsed/refractory (R/R) to CD19 CAR T-cell therapy. CARGO plans to commence Phase 2 pivotal trial of CRG-022 (CD22 CAR) in mid-2023 in patients with LBCL that is R/R to CD19 CAR T-cell therapy
– CD22 CAR has been granted Breakthrough Therapy Designation by the FDA, which is intended to expedite the development and review of drugs for patients with significant unmet need
– CARGO Therapeutics was launched in 2021 by Samsara BioCapital in collaboration with CAR T pioneers, Crystal Mackall, MD, and Robbie Majzner, MD, and accomplished cancer advocate, Nancy Goodman, JD
Latest News
BERKELEY, Calif. – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that the first patient has been dosed in its open-label, multicenter ANTLER phase 1 clinical trial (NCT04637763) to evaluate the company’s lead product candidate, CB-010, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL)....
SHANGHAI, China — CARsgen Therapeutics Holdings Ltd, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that CT011, an autologous CAR T-cell product candidate against Glypican-3 (GPC3), has achieved Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA)...
Paris, France – CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces preclinical results in the testing of the combination of SonoCloud® technology with immunotherapies. This laboratory work was done in collaboration with Dr Amy Heimberger – a renowned expert in...
Shijiazhuang, China – A teenage girl was diagnosed with concomitant Wilson disease (WD) and systemic lupus erythematosus (SLE), according to a case report published in Frontiers in Pediatrics. The 17-year-old patient was initially diagnosed with SLE following positive tests for lupus anticoagulant and antinuclear antibodies, along with pleural effusion, hypocomplementemia,...
The use of tyrosine kinase inhibitor (TKI) therapy may provide a degree of protection against COVID-19 in patients with chronic myeloid leukemia (CML). These findings are suggested by in a case report and literature review published in the European Journal of Case Reports in Internal Medicine. The case report involved a...
CLEVELAND, Ohio – Oral cancers and precancerous mouth lesions are considered especially difficult to diagnose early and accurately. For one, biopsies are expensive, invasive, stressful for the patient and can lead to complications. They’re also not feasible if repeated screenings of the same lesion are required. But a team of...
São Paulo, Brazil – Analysis of occurrence and co-occurrence patterns shows the highest-risk clusters of chikungunya and zika in Brazil spreading from the Northeast to the Center-West and coastal areas of São Paulo state and Rio de Janeiro state in the Southeast between 2018 and 2021, and increasing again in...
ROCKVILLE, Md. and BEIJING – CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose escalation and expansion study of CID-103, an investigational novel anti-CD38 monoclonal antibody, in patients with previously treated, relapsed or refractory...
BEIJING, China and LUND, Sweden — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for...